Prof. Xinghua Pan
Medical Science Division, Macau University of Science and Technology, Macao, China
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
30Years (1997-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications29 April 2015 in Nature
Journal Article
NGNicola Gagliani
Nicola Gagliani
MVMaria Carolina Amezcua Vesely
Maria Carolina Amezcua VeselyAIAndrea Iseppon
Andrea Iseppon
LBLeonie Brockmann
Leonie Brockmann
HXHao Xu
Hao Xu
RFRichard A. Flavell
Richard A. Flavell +17
10 December 2020 in Nature Communications
Journal Article
YZYan Zhou
Yan Zhou
DYDong Yang
Dong Yang
QYQingcheng Yang
Qingcheng Yang
XLXiao-Bin Lv
Xiao-Bin LvWHWentao Huang
Wentao Huang
HHHaiyan Hu
Haiyan Hu +22
Osteosarcoma is the most frequent primary bone tumor with poor prognosis. Through RNA-sequencing of 100,987 individual cells from 7 primary, 2 recurrent, and 2 lung metastatic osteosarcoma lesions, 11 major cell clusters are identified based on unbiased clustering of gene expression profiles and canonical markers. The transcriptomic properties, regulators and dynamics of osteosarcoma malignant cells together with their tumor microenvironment particularly stromal and immune cells are characterized. The transdifferentiation of malignant osteoblastic cells from malignant chondroblastic cells is revealed by analyses of inferred copy-number variation and trajectory. A proinflammatory FABP4+ macrophages infiltration is noticed in lung metastatic osteosarcoma lesions. Lower osteoclasts infiltration is observed in chondroblastic, recurrent and lung metastatic osteosarcoma lesions compared to primary osteoblastic osteosarcoma lesions. Importantly, TIGIT blockade enhances the cytotoxicity effects of the primary CD3+ T cells with high proportion of TIGIT+ cells against osteosarcoma. These results present a single-cell atlas, explore intratumor heterogeneity, and provide potential therapeutic targets for osteosarcoma.
1 February 2014 in Cell
Journal Article
SGShangqin Guo
Shangqin GuoXZXiaoyuan Zi
Xiaoyuan Zi
VSVincent P. Schulz
Vincent P. SchulzJCJijun Cheng
Jijun Cheng
MZMei Zhong
Mei Zhong
JLJun Lu
Jun Lu
+8
29 August 2013 in Cell Death & Disease
Journal Article
YWY Wang
Y WangFYF Yang
F Yang
HZH-X Zhang
H-X Zhang
XZX-Y Zi
X-Y Zi
Xinghua PanYHYiping Hu
Yiping Hu +4
Metal and its oxide nanoparticles show ideal pharmacological activity, especially in anti-tumor therapy. Our previous study demonstrated that cuprous oxide nanoparticles (CONPs) selectively induce apoptosis of tumor cells in vitro. To explore the anti-tumor properties of CONPs in vivo, we used the particles to treat mouse subcutaneous melanoma and metastatic lung tumors, based on B16-F10 mouse melanoma cells, by intratumoral and systemic injections, respectively. The results showed that CONPs significantly reduced the growth of melanoma, inhibited the metastasis of B16-F10 cells and increased the survival rate of tumor-bearing mice. Importantly, the results also indicated that CONPs were rapidly cleared from the organs and that these particles exhibited little systemic toxicity. Furthermore, we observed that CONPs targeted the mitochondria, which resulted in the release of cytochrome C from the mitochondria and the activation of caspase-3 and caspase-9 after the CONPs entered the cells. In conclusion, CONPs can induce the apoptosis of cancer cells through a mitochondrion-mediated apoptosis pathway, which raises the possibility that CONPs could be used to cure melanoma and other cancers.
1 April 2014 in Developmental Cell
Journal Article
JDJiameng Dan
Jiameng Dan
YLYifei Liu
Yifei Liu
NLNa Liu
Na Liu
MCMaria Chiourea
Maria Chiourea
MOMaja Okuka
Maja Okuka
LLLin Liu
Lin Liu +16
1 June 2018 in Precision Clinical Medicine
Journal Article
JZJialing Zhang
Jialing ZhangSSStephan Stanislaw Späth
Stephan Stanislaw Späth
SMSadie L Marjani
Sadie L Marjani
WZWengeng Zhang
Wengeng ZhangXinghua PanCancer is a heterogeneous disease with unique genomic and phenotypic features that differ between individual patients and even among individual tumor regions. In recent years, large-scale genomic studies and new next-generation sequencing technologies have uncovered more scientific details about tumor heterogeneity, with significant implications for the choice of specific molecular biomarkers and clinical decision making. Genomic heterogeneity significantly contributes to the generation of a diverse cell population during tumor development and progression, representing a determining factor for variation in tumor treatment response. It has been considered a prominent contributor to therapeutic failure, and increases the likelihood of resistance to future therapies in most common cancers. The understanding of molecular heterogeneity in cancer is a fundamental component of precision oncology, enabling the identification of genomic alteration of key genes and pathways that can be targeted therapeutically. Here, we review the emerging knowledge of tumor genomics and heterogeneity, as well as potential implications for precision medicine in cancer treatment and new therapeutic discoveries. An analysis and interpretation of the TCGA database was included.
About Me
CURRENT POSITION AND WORKING EXPERIENCES:
Xinghua Pan, PhD, MD, Professor, Precision Regenerative Medicine Research Centre (PRMRC), Medical Science Division (MSD), also affiliated to State Key Laboratory of Quality Research in Chinese Medicine (SKL-QRCM), in Macau University of Science and Technology (MUST), Macao 999078, China. He is a Supervisor for PhD candidate in Biomedical Science program in Faculty of Medicine, and a Supervisor for PhD of Pharmacy and for Master candidate in Faculty of Pharmacy in MSD, MUST.
Prior to this from 2017-2024, Dr. Pan served as the Chairman and a Professor of Department Biochemistry and Molecular Biology, Southern Medical University (SMU), in Guangzhou, China, wherein he was the founding Director of Guangdong Provincial Key Laboratory of Single Cell Technology and Application (2018-2025), currently Vice Chairman of its Academic Committee, and an adjunct Professor there. In SMU he was initially appointed as the Director of the Guangdong Provincial Key Laboratory of Biochip in SMU.
From 2004 to 2017, he entered as an Associate Research Scientist serving at Department of Genetics of Yale University School of Medicine, USA, then promoted to be a Research Scientist by Yale University, while also being a member of Yale Center Excellence in Genomics, Cancer Center, and Stem Cell Center.
Social Links
